NCT06397859View on ClinicalTrials.gov

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

RecruitingOBSERVATIONAL
Enrollment

266

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions
Hepatitis D
Interventions
DRUG

Bulevirtide

dose of 2 mg/day subcutaneously

Trial Locations (1)

20122

RECRUITING

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy., Milan

All Listed Sponsors
lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER